FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

BIOMARKERS is a distinguished journal published by Taylor & Francis Ltd, focusing on the critical intersection of biochemistry, clinical biochemistry, and health-related toxicology. With a robust history of publication since 1996 and ongoing contributions through to 2024, the journal serves as a vital platform for researchers, professionals, and students keen on exploring innovative biomarker research that spans various domains within the life sciences. The journal is currently ranked in the Q3 quartile in key areas such as Biochemistry and Health, demonstrating its reputation in the scientific community. Although it operates under a subscription model, BIOMARKERS remains an essential resource for advancing knowledge on biomarkers in health and disease, reflecting the latest advancements and methodologies within the rapidly evolving landscape of biomedical research. Researchers looking to publish in this influential journal can expect a rigorous peer-review process aimed at ensuring the dissemination of high-quality scientific inquiry.

Current Issues in Pharmacy and Medical Sciences is a prominent open-access journal published by SCIENDO, dedicated to advancing knowledge and understanding in the fields of pharmacy, biochemistry, molecular biology, and medicine. With an ISSN of 2084-980X and an E-ISSN of 2300-6676, this journal provides a platform for researchers and academics to disseminate current findings and methodologies shaping the future of these disciplines. Since its inception in 2012 and having established itself as an open-access journal since 2014, Current Issues in Pharmacy and Medical Sciences has been committed to providing high-quality, peer-reviewed content that fosters innovation and scholarly collaboration, even as it currently ranks in the Q4 category across several key areas, including Pharmacology and Biochemistry. The journal's findings are particularly relevant to professionals and students aiming to stay abreast of the latest trends and issues impacting healthcare and pharmaceutical sciences. With future issues anticipated until 2024, this journal is positioned as a vital resource for anyone engaged in the pharmaceutical and medical fields and contributing to meaningful advancements.

JCI Insight, published by the American Society for Clinical Investigation, stands as a vital resource in the field of medicine, having achieved a prestigious Q1 rating in the 2023 category for miscellaneous medicine. With an impressive Scopus rank of 27 out of 636, placing it in the 95th percentile, this journal emphasizes the dissemination of high-quality, peer-reviewed research that pushes the boundaries of clinical and translational science. Since becoming an Open Access journal in 2020, JCI Insight has expanded its reach, providing researchers, professionals, and students around the globe with unfettered access to groundbreaking studies and reviews. The journal focuses on a wide spectrum of topics relevant to the medical community, making it an essential platform for sharing innovative findings and fostering collaboration among scientists dedicated to transforming health outcomes. Based in Ann Arbor, Michigan, JCI Insight continues to inspire advancements in medical research, contributing significantly to the ongoing dialogue in the ever-evolving healthcare landscape.

Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Advanced Biomedical Research, published by Wolters Kluwer Medknow Publications, is a prominent open access journal dedicated to advancing the field of biomedical research since its inception in 2012. With an ISSN of 2277-9175, this journal serves as a vital platform for researchers, professionals, and students to disseminate high-quality research findings and innovative ideas in a variety of topics within biochemistry, genetics, and molecular biology. Recognized within the Q3 category of the 2023 journal quartile rankings, it ranks 365th among general medicine journals and 187th in the general fields of biochemistry and genetics, underscoring its commitment to fostering scientific dialogue and collaboration. With its open access model, Advanced Biomedical Research ensures that research is readily accessible to a global audience, thereby enhancing the visibility and impact of scholarly work. As the journal continues to evolve through its converged editorial focus from 2019 to 2024, it aims to play a critical role in shaping the future of biomedical sciences in India and beyond.

Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.